NCT02694536View on ClinicalTrials.gov

A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

August 1, 2006

Primary Completion Date

November 19, 2009

Study Completion Date

November 19, 2009

Conditions
Pancreatic Cancer
Interventions
DRUG

Erlotinib

Participants will receive erlotinib tablets as 100 milligrams (mg) orally (PO) once daily.

DRUG

Gemcitabine

Participants will receive gemcitabine as 1000 milligrams per meter-squared (mg/m\^2) via intravenous (IV) infusion on Days 1, 8, 15, 22, 29, 36, and 43 of the first 8-week cycle, and thereafter on Days 1, 8, and 15 of every 4-week cycle.

Trial Locations (11)

27100

Pavia

33170

Pordenone

37126

Verona

40138

Bologna

44124

Cona (Ferrara)

56100

Pisa

70124

Bari

80131

Napoli

95126

Catania

00144

Rome

06156

Perugia

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02694536 - A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter